New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:52 EDTMRK, INCYIncyte and Merck enter into collaboration for INCB24360 and MK-3475
Incyte (INCY) announced that it has entered into a clinical trial collaboration agreement with Merck (MRK), through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer, or NSCLC, and other advanced or metastatic cancers. Both INCB24360 and MK-3475 are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer.
News For INCY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 28, 2015
07:59 EDTMRKMerck HCV data supports NDA filing, says SunTrust
SunTrust believes that Merck's C-EDGE & C-SURFER efficacy data at EASL indicates that the company's HCV treatment is competitive with Gilead's (GILD) single pill dose and superior to AbbVie's (ABBV) Viekira Pak. The firm says the data supports Merck's imminent NDA filing with breakthrough designation, potentially enabling a 2H15 launch. It keeps a $72 price target and Buy rating on the shares.
07:03 EDTMRKMerck sees FY15 EPS $3.35-$3.48, consensus $3.37
Sees FY15 revenue $38.3B-$39.8B, consensus $39.2B.
07:02 EDTMRKMerck reports Q1 EPS 85c, consensus 74c
Subscribe for More Information
April 27, 2015
18:56 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
18:32 EDTMRKMerck announces publication of pivotal data from Zerbaxa Phase 3 clinical study
Subscribe for More Information
17:13 EDTMRKMerck announces Januvia study achieved primary endpoint
Merck announced that the trial evaluating cardiovascular outcomes with Sitagliptin, or TECOS, of Merck's DPP-4 inhibitor, Januvia, or sitagliptin, achieved its primary endpoint of non-inferiority for the composite cardiovascular endpoint. Among secondary endpoints, there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo. The complete results of TECOS will be presented on June 8 at the Scientific Sessions of the American Diabetes Association. TECOS was an event-driven trial conducted in adults with type 2 diabetes and a history of cardiovascular disease. The study was designed to assess the CV safety of long-term treatment with Januvia as part of usual diabetes care compared with usual care without Januvia. The primary endpoint was the composite of time to the first of any of the following confirmed events: cardiovascular-related death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. TECOS enrolled 14,724 participants from 38 countries between December 2008 and July 2012. The median patient follow-up was approximately three years.
15:04 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
13:43 EDTMRKEarnings Watch: Merck shares lower by about 5.6% since last earnings report
Subscribe for More Information
09:37 EDTMRKBarclays healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
06:19 EDTMRKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
07:58 EDTMRKMerck May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
05:35 EDTMRKMerck Phase 3 C-EDGE program shows high sustained virologic responses
Subscribe for More Information
April 23, 2015
16:39 EDTMRKACETO subsidiary to launch Timolol Maleate Ophthalmic Solution
Subscribe for More Information
05:40 EDTMRKMerck announces results from C-SURFER Phase 2/3 study
Subscribe for More Information
April 22, 2015
08:18 EDTMRKOrganovo enters into a collaboration agreement with Merck Sharp and Dohme
Subscribe for More Information
April 21, 2015
08:30 EDTMRKMerck reaffirms commitment to developing medicines for infectious diseases
Merck reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year’s 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company’s broad portfolio of marketed and investigational anti-infective medicines. Merck completed its acquisition of Cubist Pharmaceuticals, Inc. on Jan. 21, 2015, and continues to build on both companies’ work in infectious disease. Antimicrobial research remains an important area of focus. In addition to a combined portfolio of antibiotic and antifungal medicines, vaccines, and medicines for HIV and HCV, Merck has multiple programs that span discovery through late-stage development. In total, Merck currently has more than 15 ongoing clinical trials evaluating antibiotic, antifungal and antiviral agents for the prevention and treatment of infectious disease. These trials are projected to enroll approximately 8,000 patients.
05:57 EDTINCYIncyte price target raised to $121 from $80 at Piper Jaffray
Subscribe for More Information
April 20, 2015
08:47 EDTINCYIncyte price target raised to $120 from $93 at SunTrust
Subscribe for More Information
08:05 EDTMRKTetraLogic, Merck enter into oncology clinical study collaboration
Subscribe for More Information
07:20 EDTMRKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use